Dr. John Bondo Hansen is a seasoned Medicinal Chemist and formally Vice President of Medicinal Chemistry at Novo Nordisk. Dr. Hansen worked in drug discovery in positions of increasing responsibility. He was the co-founder and member of management of several companies including Contera Pharma, which was acquired by Bukwang Pharma of Korea in 2014.
An Oncology biotech pioneering RAD51 inhibition and other DDR mechanisms
